Enfusion Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Enfusion Inc (ENFN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Enfusion Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 201M vs 141M combined for tracked competitors (58.8% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+6.7% annualized vs trailing 12 months), vs accelerating (+276.6%) for its tracked peer group.
- Growth: Enfusion Inc generated 15.0% revenue growth year over year in Q4 2024, vs -6.4% for its tracked competitors combined.
- Profitability: Its 0.3% net margin compares with -32.3% for the peer group.
- Peer revenue share: Enfusion Inc accounted for 28.8% of combined revenue among its tracked peer group, up from 24.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.18M compares with $0.40M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ENFN Sales vs. its Competitors, Q4 2024
Enfusion Inc reported revenue growth of 14.99 % year on year in Q4 2024, above its competitors' combined revenue change of -6.38 %.
With a net margin of 0.32 %, Enfusion Inc achieved higher profitability than its competitors (-32.26 %).
Enfusion Inc generated 28.79 % of the combined sales of its peer group, up from 24.76 % a year earlier.
Enfusion Inc vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Enfusion Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Enfusion inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Enfusion Inc's competitor groups requires a Commercial License.
For context: the Software & Programming industry grew revenue 16.0% year over year, combined, vs 15.0% for Enfusion Inc. Enfusion Inc's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Enfusion Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Enfusion inc | Yes | Yes | Yes | No |
| Competitors combined (1) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ENFN Stock Performance relative to its Competitors
ENFN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Agora Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Enfusion Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Enfusion Inc's Comment on Competition and Industry Peers
flexibility of solution;
quality of professional services;
depth of product functionality and asset coverage;
speed of implementations and client support;
innovation and responsiveness to client needs;
return on investment and total cost of ownership;
security and reliability;
integration and interoperability with third-party systems; and
ability to support regulatory requirements and compliance.
We believe that we compete favorably with respect to these factors. However, many of our competitors have greater financial, technical and other resources, greater brand recognition, larger sales forces and marketing budgets and broader distribution networks. They may be able to leverage these resources to gain business in a manner that discourages customers from purchasing and implementing our solution. Furthermore, we expect that our industry will continue to attract new market entrants, including smaller emerging companies, which could introduce new offerings. We may also expand into new markets and encounter additional competitors in such markets.
Incumbents such as Blackrock?s Aladdin, Broadridge, State Street Alpha, SS&C and SimCorp may provide end-to-end systems, but they are single-tenant and cloud-migrated rather than cloud-native or built for the cloud. As a result, they are not sufficiently nimble to allow for scale and often require physical provisioning, rely on large teams of specialized personnel that through time are difficult to hire, face latency issues and continue to increase the investment manager?s overall costly and inefficient legacy technology dependencies. Their single tenant and cloud-migrated structures restrict their agility and inhibit their ability to provide frequent or simultaneous upgrades to all of their clients. New entrants in the space often provide single point solutions such as trading, fund administration or portfolio analytics that are intended to be coupled with other offerings.
We believe our multi-tenant cloud-native solution, comprised of mission critical systems integrated with a suite of services, is highly differentiating. Our cloud-native, single codebase architecture allows us to serve the full investment lifecycle in a way that unifies workflows creating one dataset that accurately reflects the activities across all systems and multiple departments within a client organization in real time. Additionally, our single codebase architecture allows us to deliver faster implementation and continuously add functionality. As a result, we believe Enfusion is able to continue to innovate faster, delivering a better, more nimble solution that investment managers require in light of the global challenges they face.
Publicly Traded Peers of Enfusion inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Enfusion inc | 1,414.69 | 200.74 |
| Agora Inc | 1,640.99 | 140.66 |
| SUBTOTAL | 3,055.68 | 341.40 |
Sources: Enfusion inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Enfusion inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Enfusion Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Enfusion inc | 1,415 | 182,157 | 3,553 |
| Agora Inc | 1,641 | 401,897 | 27,223 |
| PEERS TOTAL | 1,641 | 401,897 | 27,223 |
Enfusion Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Agora Inc | CN 46.95 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Enfusion Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 236 companies in Enfusion Inc's industry classification, broader than the peer set above. Market cap in millions of $.Enfusion Inc ranks #0 of 236 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,661, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Microsoft Corporation | 3,756,759 | 50.30 % |
| 2 | Palantir Technologies Inc | 486,305 | 6.51 % |
| 3 | Oracle Corporation | 388,902 | 5.21 % |
| 4 | Sap Se | 268,701 | 3.60 % |
| 5 | Crowdstrike Holdings Inc | 1,234 | 5.2% |
| 6 | Salesforce Inc | 1,234 | 5.2% |
| 7 | Shopify Inc | 1,234 | 5.2% |
| 8 | Full Truck Alliance Co Ltd | 1,234 | 5.2% |
| 9 | Servicenow Inc | 1,234 | 5.2% |
| 10 | Cloudflare Inc | 1,234 | 5.2% |
| 0 | Enfusion inc | 1,013 | 0.00 % |
Market cap and industry share for the rest of Enfusion Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-04-17.
Enfusion Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Software & Programming industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (343 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 68.12 % | 64.28 % (avg) | +3.8 pp |
| Operating Margin | 3.07 % | industry median | +9.2 pp |
| EBITDA Margin | 8.81 % | 2.53 % (avg) | +6.3 pp |
| Capital Intensity (Capex / Revenue) | 1.81 % | 4.79 % (avg) | -3.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Enfusion Inc's Valuation vs Competitive Position
Valuation multiples vs the Software & Programming industry average (343 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 357.4x | 39.5x | +317.9x |
| EV / EBITDA | 78.0x | 21.7x | +56.3x |
| P/B | 15.5x | 5.4x | +10.1x |
| Return on Equity | 4.26 % | industry aggregate | -15.30 % |
| Return on Invested Capital | 2.76 % | -0.26 % (avg) | 3.02 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Enfusion Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | 34.60 % | 15.66 % | 15.44 % |
| Operating Margin | - | -7.96 % | 6.87 % | 3.07 % |
| Return on Invested Capital | - | -4.92 % | 6.05 % | 2.76 % |
| P/E | - | - | 124.5x | 357.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Enfusion Inc's Strategic Group Map
Every company in Enfusion Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Enfusion Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Enfusion Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,661 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.81 % vs industry average 4.79 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Enfusion Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Enfusion Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Enfusion Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Enfusion Inc falls in the Medium attractiveness / High strength cell: Invest / Grow.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Enfusion Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 9.2 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+6.7% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 15.3 points below the industry aggregate.
Opportunities
- Industry revenue growing at a healthy 11.6% median pace.
Threats
- Industry dominated by Microsoft Corporation, holding 50.30 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Enfusion Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Enfusion inc | 1.97 | 3.76 | - |
| Agora Inc | 1.34 | 4.58 | 0.14 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Enfusion Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Enfusion inc | Q4 2024 | +15.0 % | -80.9 % |
| Agora Inc | Q4 2025 | +6.2 % | - |
| PEERS TOTAL | +8.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Enfusion Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Enfusion inc | Q4 2024 | +8.3 % | -26.1 % |
| Agora Inc | Q4 2025 | -0.9 % | -33.2 % |
Enfusion Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Enfusion inc | 3.08% | 2.98% | 4.26% |
| Agora Inc | 1.32% | 1.43% | 1.69% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Enfusion Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Enfusion inc | 355.66 | 7.05 |
| Agora Inc | 207.50 | 11.67 |
| PEERS AVERAGE | 227.31 | 8.95 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.